Novo Nordisk reported the results of a trial of an experimental obesity drug after an earlier failure sent shares tumbling. One of the experimental drugs helped patients lose almost 20% of their weight after 24 weeks. In a phase three clinical trial of Cagrilintide, patients lost an average of 11.8% weight after 68 weeks, compared to 2.3% on placebo. Cagrilintide mimics the hormone amylin, induces a feeling of satiety, and is administered by weekly injection. Another study, STEP UP, showed a mean weight loss of 20.7% after 72 weeks in non-diabetic obese patients on semaglutide 7.2 mg. In the OASIS 4 study, the semaglutide pill resulted in a 16.6% weight loss after 64 weeks in obese or overweight patients. Most patients tolerated these drugs well.